Data as of Jan 29
| +0.003 / +0.41%|
Rexahn Pharmaceuticals, Inc. is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The company currently has three clinical stage oncology candidates, Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
|Chang Ho Ahn||Chairman & Chief Scientist|
|Peter David Suzdak||Chief Executive Officer & Director|
|Rakesh Soni||President & Chief Operating Officer|
|Tae Heum Jeong||Chief Financial Officer, Secretary & Senior VP|